Forward-Looking Statements This presentation contains express or implied forward looking statements of Septerna, Inc. (the "Company," "we," or "our") within the meaning of the Private Securities Litigation Reform Act of

Nasdaq: SEPN Pioneering a New Era of

GPCR Drug Discovery March 2025 TD Cowen 45th Annual Health Care Conference Exhibit 99.1

Forward-Looking Statements This

presentation contains express or implied forward looking statements of Septerna, Inc. (the "Company," "we," or "our") within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.

All statements other than statements of historical facts contained in this presentation, including statements regarding our business strategy, plans, estimated milestones and objectives of management are forward-looking statements. Such

forward-looking statements include, but are not limited to, statements regarding: the continued development and advancement of our oral small molecule GPCR-targeted programs; the initiation, timing, progress, and results of conducting our research

and development programs (including our investigation into the underlying mechanism of the elevated unconjugated bilirubin observed for SEP-786) and our current and future preclinical studies and anticipated clinical trials (including the selection

and advancement of our next-generation oral PTH1R agonist product candidate and projected initiation of the SEP-631 clinical trial), and the release of data related thereto; our ability to demonstrate, and the timing of, preclinical proof-of-concept

in vivo and ex vivo for multiple programs; the potential of our proprietary Native Complex Platform ; the accuracy of our estimates regarding expenses and capital requirements, including our expected cash runway; the size and growth potential

of the markets for our current and future product candidates and our ability to serve those markets; and our expectations regarding the implementation of our business model, and strategic plans for our business, product candidates, and technology.

Such forward-looking statements reflect the current views of the Company and are subject to known and unknown risks and other factors, which are, in some cases, beyond the Company's control. Risks that contribute to the uncertain nature of the

forward-looking statements include those risks and uncertainties set forth in the section titled "Risk Factors" in our most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the Securities and Exchange

Commission (the "SEC") and in our subsequent filings with the SEC. Certain information in this presentation (including market data and statistical information) and statements made orally during this presentation are the good faith

estimates of management and have been obtained from various sources (including third-party sources such as independent industry publications, governmental publications, and reports by market research firms), and we do not guarantee the accuracy or

completeness of such information. No representations or warranties (expressed or implied) are made about the accuracy of such forward-looking statements, and there can be no assurance as to the reliability or correctness of such projections and

actual results may vary materially from those projected. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Septerna: Pioneering a New Era

of GPCR Drug Discovery with Oral Small Molecules Native Complex Platform designed to unlock the full potential of GPCR therapies Iterative structure-based drug design to rapidly optimize and validate programs in animal models Portfolio

strategy to drive value creation Validated targets + early clinical readouts + multi-billion $ market opportunities Well-capitalized with planned operating runway into at least 2H 2027 GPCR = G protein-coupled receptor; Discovery Stage TSHR

NAM: Potential first disease-modifying treatment for Graves' disease and TED Incretin Receptor Agonists: Opportunities for single- and multi-incretin receptor agonists for metabolic diseases (e.g., obesity and T2D) Lead Programs PTH1R

Agonists: Potential first-in-class oral small molecule for hypoparathyroidism; plan to select a next-generation candidate to accelerate toward clinical development later this year SEP-631 MRGPRX2 NAM: Pipeline-in-a-product opportunity for mast

cell diseases (e.g., CSU); Phase 1 initiation expected in 2025 NAM = negative allosteric modulator; TED = thyroid eye disease; CSU = chronic spontaneous urticaria; T2D = Type 2 diabetes

GPCR Drug Discovery Success Has Been

Highly Concentrated to a Small Fraction of GPCRs Historically productive target class, yet substantial untapped opportunity to expand the number of druggable GPCRs >70% of GPCR drugs target 6 small subfamilies of GPCRs ~1/3 of all FDA-approved

drugs (~500 approved products) target GPCRs ~75% of potential GPCR targets remain undrugged Our focus: Unlocking difficult-to-drug GPCRs with our Native Complex Platform

Proprietary Native Complex

Platform Today's GPCR Drug Discovery Challenge Several new small molecule drug discovery technologies have largely been inaccessible to GPCRs Inability to isolate fully functional GPCR proteins significantly limits use of modern

discovery tools G protein Lipid Bilayer Ligand GPCR Native Complex Platform : Industrialized Workflows to Unlock Difficult-to-Drug GPCRs Native Complexes Retain GPCR natural structure, function, and dynamics High-Resolution GPCR Structures

Technologies to Screen Billions of Compounds Discovery of new leads with relevant modes of action Novel binding pockets and new insights into GPCR modulation Structure-Based Drug Design & Optimization <1 year from initiation of med chem to

activity in animal models for each program to date

Native Complex Platform is a

Highly Efficient Platform for GPCR Structure-based Drug Design New Small Molecule Ligand New Ligand-Bound GPCR Structure ~1-2 weeks Native Complex Cryo-EM Structure-Based Design Rapid Iterative Cycle Apo (no ligand) Agonist Positive Allosteric

Modulator Antagonist Negative Allosteric Modulator GPCR A 4 8 12 16 20 B C D E F G # Structures 24 Native Complex High-Resolution GPCR Structures cryo-EM = cryogenic electron microscopy GPCR cryo-EM now achieving resolutions relevant for

structure-based drug design Native Complex cryo-EM enables rapid and iterative lead optimization Applies to a broad range of lead candidate modes of action (e.g., agonists, antagonists, allosteric modulators)

Advancing a Deep Portfolio of Oral

Small Molecule GPCR-Targeted Programs Programs Development Status a Program / Target Mode of Action Therapeutic Area Indications / US Patient Population Discovery IND-enabling Phase 1 PTH1R Agonist Endocrinology Hypoparathyroidism: ~70k SEP-631

(MRGPRX2) Negative Allosteric Modulator Immunology and Inflammation CSU: ~1.5mm Other mast cell diseases TSHR Negative Allosteric Modulator Endocrinology Graves' disease: ~2mm Thyroid eye disease: ~1mm GLP-1R, GIPR, GCGR Single- and

Multi-Agonists Metabolic Diseases Obesity and T2D: ~800mm (worldwide) Other metabolic diseases Other Therapeutic Areas of Interest / Focus: Neurology, Women's Health, Cardiovascular Disease and Respiratory Disease Note: Vertex acquired an

undisclosed discovery-stage program in 2023 for $47.5M upfront

PTH1R Agonist Program Oral Small

Molecule Targeting PTH1R for Hypoparathyroidism

Hypoparathyroidism: Significant Unmet

Need for an Oral PTH Replacement Hypoparathyroidism: Low PTH leads to low blood calcium ~70K patients in US; ~140K patients in EU Challenging patient symptoms Muscle cramps, tingling, brain fog Life-threatening complications: cardiac arrhythmias,

seizures Inadequate standard-of-care Calcium supplements (high doses several times per day) and Vitamin D do not fully resolve symptoms, and lead to complications including calcifications and renal impairment Injectable PTH therapies approved and in

development Will require life-long injections Our Strategy: Functionally replace PTH with oral small molecule PTH1R agonist to normalize serum calcium PTH = Parathyroid Hormone PTH: Master Regulator of Blood Calcium

Discontinuation of SEP-786

Development to Focus on Advancing Next-Generation Oral Small Molecule PTH1R Agonist Decision to discontinue SEP-786 Phase 1 SAD/MAD trial in healthy volunteers No Serious Adverse Events across all participants 2 unanticipated severe (Grade 3) events

of elevated unconjugated bilirubin levels in MAD; believed to be SEP-786 off-target effect Both events were reversible and without liver injury (normal AST, ALT, GGT), cholestasis, or hemolysis No predicted risk of elevated bilirubin from all

preclinical studies including 28-day GLP toxicology studies in rats and dogs Non-clinical studies underway to investigate underlying mechanism of observed effects Early signals of on-target pharmacology seen for SEP-786 prior to trial

discontinuation Observed initial increases in serum calcium and decreases in endogenous PTH (as anticipated for healthy subjects) Favorable human PK profile consistent with preclinical predictions to support QD or BID dosing Well-positioned to

quickly pivot to next-generation oral PTH1R agonist Native Complex discovery efforts identified multiple chemically diverse PTH1R agonists Multiple candidate-quality leads with chemical structures unrelated to SEP-786, activity in animal models, and

excellent pharmaceutical properties

Native Complex Platform

Identified Broad Portfolio of Chemically Distinct PTH1R Agonists Structurally unrelated to SEP-786 Potent, selective, oral small molecule Normalizes serum calcium in preclinical animal models PK/PD projects full-day calcium control in

hypoparathyroidism patients with QD or BID dosing Safe and well tolerated in preclinical toxicology studies PTH1R Next-Gen PTH1R Agonist Target Candidate Features Multiple PTH1R agonists with distinct binding sites Native Complex Hit Identification

Optimization of Multiple Next-Generation Compounds Multiple PTH1R agonist series optimized in parallel Native Complex Structure-Based Design Rapid Iterative Structure-Based Drug Discovery <1 year from initiation of medicinal chemistry to activity

in an animal model QD = once-daily dosing BID = twice-daily dosing PK = pharmacokinetics PD = pharmacodynamics Multiple leads optimized toward development candidate selection

Potent, Selective Next-Generation

PTH1R Agonists Normalize Serum Calcium and Phosphate in Hypoparathyroidism Animal Model Surgery to remove parathyroid glands Rat Decreased serum calcium (hypocalcemia) Oral small molecule PTH1R agonist Normalize serum calcium Rat surgical model of

hypoparathyroidism PO = oral dosing QD = once daily dosing BID = twice daily dosing Example Next-Generation PTH1R Agonist: 28-day Dosing Sustained Normalization of Serum Ca2+ Levels Sustained Normalization of Serum Phosphate Levels Next-gen PTH1R

agonist: activity at 0.15 mg/kg QD comparable to SEP-786 at 3 mg/kg BID

Multiple Next-Generation PTH1R

Agonists with Distinct Chemical Structures and Favorable Pharmacokinetics Profiles Example Next-Generation PTH1R Agonist PK Profiles PK studies in mice, rats, dogs, and cynomolgus monkeys support predicted human PK for QD or BID dosing Next-Gen

PTH1R Agonist #1 Next-Gen PTH1R Agonist #2 Parameter Mouse Rat Dog Cyno Mouse Rat Dog Cyno Oral Bioavailability (%F) 91 56 88 68 90 93 77 56 PO Half-life (hr) 7.8 17 24 14 7.2 14 39 17 SEP-786 Mouse Rat Dog Cyno 54 26-50 40-60 44 4.6 4-8 5-7 8.2 vs.

Predicted Human PK PO Half-life 9-27 hours Predicted Human PK PO Half-life 43-87 hours Predicted Human PK PO Half-life 17-34 hours Observed Human PK (Ph 1) PO Half-life ~18 hours vs. Next-gen PTH1R agonists: human PK properties (e.g., oral

bioavailability and half life) predicted to be superior to SEP-786 Plan to select a next-generation candidate to accelerate toward the clinic later this year

SEP-631: Oral Small Molecule

MRGPRX2 NAM Targeting MRGPRX2 for Mast Cell Disorders, Including CSU

MRGPRX2: Emerging Target for Mast

Cell-Driven Diseases MRGPRX2 Highly and uniquely expressed on mast cells Distinct from IgE / allergen pathway Multiple endogenous agonists Mast Cell-Driven Diseases CSU, atopic dermatitis, allergic asthma, and others CSU: Significant Unmet Need ~1.5

million patients in US Itchy, painful hives and angioedema Chronic symptoms can impact quality of life First-line treatment: antihistamines; 37% refractory Second-line treatment: anti-IgE (Xolair); 64% refractory Our Strategy: MRGPRX2 NAM Inhibit

mast cell activation by selectively blocking MRGPRX2 NAM= Negative Allosteric Modulator

SEP-631: Oral Small Molecule

MRGPRX2 NAM Designed to Stop MRGPRX2-Mediated Mast Cell Degranulation SEP-631 Potently Inhibited Skin Extravasation in MRGPRX2 Knock-in Mouse Model Treat with oral MRGPRX2 NAM (SEP-631) or vehicle Administer Evans Blue dye Measure extravasation of

dye into skin Extravasation (no MRGPRX2 inhibition) No extravasation (MRGPRX2 inhibition) Knock-in Mouse mMRGPRB2 KO hMRGPRX2 KI SEP-631: Selective MRGPRX2 NAM Potent oral small molecule Blocked activation of all endogenous MRGPRX2 activators Showed

insurmountable NAM profile with long-lasting inhibition Effective in Preclinical Models Prevented skin extravasation in human MRGPRX2 knock-in mouse Potently inhibited degranulation of primary human mast cells Demonstrated good PK properties and has

been generally well tolerated in preclinical safety models to date Intradermal skin challenge with Cortistatin-14 (MRGPRX2 agonist) KO = gene knockout KI = gene knock-in

SEP-631: MRGPRX2 NAM with

Potentially Differentiated Profile Key Criteria SEP-631 High Potency Demonstrated in multiple functional and binding assays Broad Inhibition Long residence time and insurmountable inhibition of multiple endogenous agonists Good Oral PK Excellent

oral bioavailability; PK profile across species supports QD oral dosing projection in humans In vitro PD Activity in primary human skin mast cells In vivo PD Activity in hMRGPRX2 knock-in mice Favorable in vivo safety profile 14-day non-GLP studies

in rat and dog showed a generally favorable tolerability profile IND-enabling studies ongoing to support advancement into Phase 1 clinical trial in 2025

TSHR NAM Program Oral Small

Molecule Targeting TSHR for Graves' Disease and TED

No Disease-Modifying Therapies for

Graves' Disease and Thyroid Eye Disease (TED) Graves' Disease & TED Pathophysiology: Autoantibodies activate TSHR in thyroid gland and in orbital fibroblasts behind the eyes Graves' Disease >2M patients in US

Standard-of-care: antithyroid drugs, radioactive iodine, thyroidectomy TED Develops in ~50% of Graves' disease patients TEPEZZA (anti-IGF-1R) decreases proptosis but requires multiple IV infusions; serious side effects (e.g., hearing

loss) Drug Discovery Challenge: Each Patient Has Unique Autoantibodies High-affinity, frequently polyclonal, high titer Our Strategy: TSHR NAM Oral disease-modifying treatment for all Graves' disease and TED patients NAM= Negative Allosteric

Oral Small Molecule TSHR NAMs

Reversed Symptoms in Novel Graves' Disease Model Agonist mAb + Vehicle Agonist mAb + SP-1351 Isotype mAb control + Vehicle TSHR Activating Antibody Mouse Thyroid Hormone Levels Thyroid Size Eye Proptosis (bulging) TSHR

Activating Ab +TSHR NAM Reversal of Thyroid and Eye Manifestations 6 weeks 1 week Selective TSHR NAMs Blocked activation of TSHR by patient-derived autoantibodies Demonstrate insurmountable profiles Preclinical Leads Inhibited Diverse Patient

Autoantibodies Fully inhibited several Graves' patient polyclonal serum samples in primary orbital fibroblasts Reversed Graves' Animal Disease Model Effects Normalization of thyroid hormone T4 Reduction in thyroid weight Reversal of

proptosis mAb = monoclonal antibody

Incretin Receptor Agonist Programs

Oral Small Molecule Single- and Multi-GLP-1R, GIPR, and GCGR Agonists for Metabolic Disorders, Including Obesity and Type 2 Diabetes

Next-Generation Oral Incretin

Receptor Agonists Incretin peptide therapeutics have been transformative treatments for obesity and diabetes Marketed GLP-1 and GLP-1/GIP products generated ~$36B in global sales in 2023 Limitations: tolerability, injection administration, prolonged

titration schemes Our Strategy: Next-generation oral small molecule single- and multi-incretin receptor agonists that can be used as single medicines or in combination Septerna Binding Site Danuglipron & Orforglipron Sites vs. Approximate %

sequence similarity across GLP-1R, GIPR, GCGR 80 - 90% 40 - 60% Novel binding pocket identified with potential to develop both single- and multi-incretin receptor agonists Pocket has higher sequence similarity across GLP-1R, GIPR, GCGR than known

binding sites occupied by clinical-stage GLP-1R small molecule agonists

Discovery of Oral Small Molecule